Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Long-Term Serologic Outcomes Following Treatment of Syphilis in People With HIV: A Prospective Cohort Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Casado José L, Vizcarra Pilar, Izuzquiza Isabel, Rodriguez-Dominguez Mario J, Romero-Hernandez Beatriz, Moreno Ana, Vallejo Alejandro
Аннотация
BACKGROUND: This study aimed to evaluate the factors associated with rate and time to serological response, serofast status, and seroreversion in people with HIV (PWH) with a first diagnosis of syphilis.
METHODS: The primary endpoint was serological response as determined by a 4-fold decline in rapid plasma regain (RPR) titer or seroreversion at 12 months. A secondary endpoint was cumulative serological response by 24 months of follow-up. Survival and multivariate analysis were used to compare different associated factors.
RESULTS: A total of 184 PWH had a first syphilis episode in 642 person-years of follow-up. After treatment, the median time to serological response was 6.53 months (95% CI 6.055-7.012). In the Cox model, only secondary syphilis (HR 3.091, 95% CI 1.330-11.440; P = .013) and higher nadir CD4+ count (HR 1.002; 95% CI 1.001-1.004; P = .043) were associated with a faster response. At 12 months, 155 PWH (84%, 95% CI 78%-89%) achieved response and a lower baseline RPR (RR 0.972; 95% CI .947-.997; P = .028) was associated with failure. After response, 79 (51%) with higher CD4+ count remained as serofast status, and 33 of them (46%) seroreverted during follow-up. Of the 29 PWH without response, 11 (38%) reached serological response in a longer follow-up (29.3 months, 95% CI 23.03-35.7), and 2 out of 4 (14%) had confirmed neurosyphilis, whereas 14 (48%) had reinfections. Thus, 89% of PWH had serological response by 24 months.
CONCLUSIONS: The time to serological response, the rate of serofast, and the outcome are the result of the interaction of nontreponemal test titers, syphilis stage, and the patient's immune status.
METHODS: The primary endpoint was serological response as determined by a 4-fold decline in rapid plasma regain (RPR) titer or seroreversion at 12 months. A secondary endpoint was cumulative serological response by 24 months of follow-up. Survival and multivariate analysis were used to compare different associated factors.
RESULTS: A total of 184 PWH had a first syphilis episode in 642 person-years of follow-up. After treatment, the median time to serological response was 6.53 months (95% CI 6.055-7.012). In the Cox model, only secondary syphilis (HR 3.091, 95% CI 1.330-11.440; P = .013) and higher nadir CD4+ count (HR 1.002; 95% CI 1.001-1.004; P = .043) were associated with a faster response. At 12 months, 155 PWH (84%, 95% CI 78%-89%) achieved response and a lower baseline RPR (RR 0.972; 95% CI .947-.997; P = .028) was associated with failure. After response, 79 (51%) with higher CD4+ count remained as serofast status, and 33 of them (46%) seroreverted during follow-up. Of the 29 PWH without response, 11 (38%) reached serological response in a longer follow-up (29.3 months, 95% CI 23.03-35.7), and 2 out of 4 (14%) had confirmed neurosyphilis, whereas 14 (48%) had reinfections. Thus, 89% of PWH had serological response by 24 months.
CONCLUSIONS: The time to serological response, the rate of serofast, and the outcome are the result of the interaction of nontreponemal test titers, syphilis stage, and the patient's immune status.